Small molecule · Inhibitor of KRAS G12C mutant protein (KRAS) · developed by Bristol
Adagrasib is an orally available small molecule that covalently binds the cysteine-12 residue of mutant KRAS G12C, locking the protein in its inactive state and blocking downstream signaling. It is studied in advanced or metastatic solid tumors, and is used in KRAS G12C-mutated non-small cell lung cancer and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Mar 25, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05263986 | Phase 1 | Advanced or Metastatic Solid Tumor | Unknown | ZLAB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid Tumor
Updated Nov 1, 2026.